PT3746467T - Péptidos de cadeia b de relaxina lipidados modificados e sua utilização terapêutica - Google Patents

Péptidos de cadeia b de relaxina lipidados modificados e sua utilização terapêutica

Info

Publication number
PT3746467T
PT3746467T PT197025935T PT19702593T PT3746467T PT 3746467 T PT3746467 T PT 3746467T PT 197025935 T PT197025935 T PT 197025935T PT 19702593 T PT19702593 T PT 19702593T PT 3746467 T PT3746467 T PT 3746467T
Authority
PT
Portugal
Prior art keywords
relaxin
therapeutic use
chain peptides
lipidated
modified
Prior art date
Application number
PT197025935T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT3746467T publication Critical patent/PT3746467T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT197025935T 2018-01-31 2019-01-30 Péptidos de cadeia b de relaxina lipidados modificados e sua utilização terapêutica PT3746467T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31

Publications (1)

Publication Number Publication Date
PT3746467T true PT3746467T (pt) 2026-01-13

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197025935T PT3746467T (pt) 2018-01-31 2019-01-30 Péptidos de cadeia b de relaxina lipidados modificados e sua utilização terapêutica

Country Status (29)

Country Link
US (3) US10961295B2 (enExample)
EP (1) EP3746467B1 (enExample)
JP (1) JP7295871B2 (enExample)
KR (1) KR102755938B1 (enExample)
CN (1) CN111770934B (enExample)
AR (1) AR114325A1 (enExample)
AU (1) AU2019214358B2 (enExample)
BR (1) BR112020014834A2 (enExample)
CA (1) CA3089657A1 (enExample)
CO (1) CO2020008308A2 (enExample)
DK (1) DK3746467T3 (enExample)
ES (1) ES3058633T3 (enExample)
FI (1) FI3746467T3 (enExample)
HR (1) HRP20260016T1 (enExample)
IL (2) IL316406A (enExample)
LT (1) LT3746467T (enExample)
MA (1) MA52994A (enExample)
MX (1) MX2020008096A (enExample)
MY (1) MY199821A (enExample)
NZ (1) NZ766762A (enExample)
PH (1) PH12020551118A1 (enExample)
PL (1) PL3746467T3 (enExample)
PT (1) PT3746467T (enExample)
RS (1) RS67606B1 (enExample)
SG (1) SG11202006903WA (enExample)
SI (1) SI3746467T1 (enExample)
TW (1) TWI763972B (enExample)
UY (1) UY38069A (enExample)
WO (1) WO2019149782A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−2を調製する方法
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
EP3131925B1 (en) 2014-04-17 2020-02-19 The Florey Institute of Neuroscience and Mental Health Modified relaxin b chain peptides
JP2017513875A (ja) * 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
JP7295871B2 (ja) 2023-06-21
PL3746467T3 (pl) 2026-04-13
EP3746467B1 (en) 2025-10-08
IL276170B1 (en) 2024-11-01
HRP20260016T1 (hr) 2026-02-27
US20210292387A1 (en) 2021-09-23
JP2021512099A (ja) 2021-05-13
LT3746467T (lt) 2026-01-26
CA3089657A1 (en) 2019-08-08
WO2019149782A1 (en) 2019-08-08
US20240218042A1 (en) 2024-07-04
MY199821A (en) 2023-11-23
CO2020008308A2 (es) 2020-10-30
KR102755938B1 (ko) 2025-01-20
MX2020008096A (es) 2020-09-24
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
CN111770934B (zh) 2024-10-18
AU2019214358B2 (en) 2023-05-25
MA52994A (fr) 2021-05-05
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01
UY38069A (es) 2019-08-30
SG11202006903WA (en) 2020-08-28
IL276170B2 (en) 2025-03-01
EP3746467A1 (en) 2020-12-09
SI3746467T1 (sl) 2026-02-27
IL316406A (en) 2024-12-01
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
PH12020551118A1 (en) 2021-07-05
ES3058633T3 (en) 2026-03-12
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
RU2020126210A (ru) 2022-02-28
IL276170A (en) 2020-09-30
US11725036B2 (en) 2023-08-15
DK3746467T3 (da) 2026-01-12

Similar Documents

Publication Publication Date Title
IL276170A (en) Lipid-adapted relaxin B peptide chains and their medical use
IL276322A (en) Lipid-like nanocomplexes and their uses
IL253712A0 (en) Mysterlein derivatives for coupling and healing
IL270244A (en) Antibody against human semaphorin 4D
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
SG11202106067UA (en) Tubulysins and protein-tubulysin conjugates
ZA201905372B (en) Therapeutic and neuroprotective peptides
SI3532059T1 (sl) Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom
GB201813312D0 (en) Compounds and their therapeutic use
IL290520A (en) Medicinal peptides
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
IL275340A (en) Peptides and other active compounds to treat pain and increase pain sensitivity
IL285144A (en) Medicinal peptides
GB201701745D0 (en) Nanoparticle-based liver-targeting therapy and imaging
IL292599A (en) tmem219 antibodies and medical uses thereof
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
IL289843A (en) Antibodies against methylthionine and their uses
IL280101A (en) Peptide compounds and therapeutic uses of same
EP3947418C0 (en) PEPTIDES AND THEIR USE
SG11202101090RA (en) Cdca1-derived peptide and vaccine containing same
GB201810635D0 (en) Peptides and cancer treatment
IL281091A (en) Peptide therapeutics for the treatment of cancer and uses thereof
GB201817486D0 (en) Peptides and conjugates
PL3732165T3 (pl) Pochodne peptydowe i ich aktywność terapeutyczna
GB201805306D0 (en) Peptides and conjugates